Outcome of complications in acromegaly patients after long-term disease remission

References

• Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-52
   PubMed Web of Science ®Google Scholar
• Melmed S. Medical progress: Acromegaly. N Engl J Med 2006;355(24):2558-73
   PubMed Web of Science ®Google Scholar
• Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970;39(153):1-16
   PubMedGoogle Scholar
• Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86(5):293-9
   PubMedGoogle Scholar
• Biermasz NR, Romijn JA, Pereira AM, Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother 2005;6(14):2393-405
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89(6):2789-96
   PubMed Web of Science ®Google Scholar
• Freda PU, Shen W, Heymsfield SB, et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 2008;93(6):2334-43
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Franck SE, de Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2014;99(10):3644-52
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754-9
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 2012;15(1):71-83
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005;90(5):2731-9
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93(1):61-7
   PubMed Web of Science ®Google Scholar
• Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005;63(4):470-6
   PubMed Web of Science ®Google Scholar
• Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992;21(3):597-614
   PubMed Web of Science ®Google Scholar
• Lopez-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997;82(4):1047-53
   PubMed Web of Science ®Google Scholar
• Ohtsuka H, Komiya I, Aizawa T, Yamada T. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocr J 1995;42(6):781-7
   PubMed Web of Science ®Google Scholar
• Kamenicky P, Viengchareun S, Blanchard A, et al. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 2008;149(7):3294-305
   PubMed Web of Science ®Google Scholar
• Maison P, Demolis P, Young J, et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 2000;53(4):445-51
   PubMed Web of Science ®Google Scholar
• Smith JC, Lane H, Davies N, et al. The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab 2003;88(6):2556-61
   PubMed Web of Science ®Google Scholar
• Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85(1):193-9
   PubMed Web of Science ®Google Scholar
• Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 2001;54(2):189-95
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006;154(3):467-77
   PubMed Web of Science ®Google Scholar
• Colao A, Terzolo M, Bondanelli M, et al. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf) 2008;69(4):613-20
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009;94(10):3746-56
   PubMed Web of Science ®Google Scholar
• Sardella C, Urbani C, Lombardi M, et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin Endocrinol (Oxf) 2014;81(4):573-81
   PubMed Web of Science ®Google Scholar
• Reyes-Vidal C, Fernandez JC, Bruce JN, et al. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab 2014;jc20142259
   Google Scholar
• Bogazzi F, Battolla L, Spinelli C, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 2007;92(11):4271-7
   PubMed Web of Science ®Google Scholar
• Maison P, Tropeano AI, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007;92(5):1743-7
   PubMed Web of Science ®Google Scholar
• Kamenicky P, Blanchard A, Frank M, et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J Clin Endocrinol Metab 2011;96(7):2127-35
   PubMed Web of Science ®Google Scholar
• Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 2008;69(3):347-58
   PubMed Web of Science ®Google Scholar
• Pereira AM, van Thiel SW, Lindner JR, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004;89(1):71-5
   PubMed Web of Science ®Google Scholar
• De ML, Bianchi A, Mazziotti G, et al. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 2008;11(1):13-20
   PubMed Web of Science ®Google Scholar
• Hayward RP, Emanuel RW, Nabarro JD. Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med 1987;62(237):41-58
   PubMedGoogle Scholar
• Jaffrain-Rea ML, Minniti G, Moroni C, et al. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 2003;148(2):193-201
   PubMed Web of Science ®Google Scholar
• Minniti G, Moroni C, Jaffrain-Rea ML, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 2001;55(3):307-13
   PubMed Web of Science ®Google Scholar
• Vianna CB, Vieira ML, Mady C, et al. Treatment of acromegaly improves myocardial abnormalities. Am Heart J 2002;143(5):873-6
   PubMed Web of Science ®Google Scholar
• Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999;84(1):17-23
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85(9):3132-40
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003;58(2):169-76
   PubMed Web of Science ®Google Scholar
• Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992;117(9):719-26
   PubMed Web of Science ®Google Scholar
• Manelli F, Desenzani P, Boni E, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999;2(3):205-10
   PubMedGoogle Scholar
• Thuesen L, Christensen SE, Weeke J, et al. The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol (Oxf) 1989;30(6):619-25
   PubMed Web of Science ®Google Scholar
• Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 2007;92(2):476-82
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Bax JJ, Biermasz NR, et al. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol 2005;153(2):231-8
   PubMed Web of Science ®Google Scholar
• Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001;86(4):1551-7
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Di Bello VPalagi C, et al. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study. Clin Endocrinol (Oxf) 2005;62(5):590-6
   PubMed Web of Science ®Google Scholar
• Ciulla MM, Epaminonda P, Paliotti R, et al. Evaluation of cardiac structure by echoreflectivity analysis in acromegaly: effects of treatment. Eur J Endocrinol 2004;151(2):179-86
   PubMed Web of Science ®Google Scholar
• Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 2003;88(7):3196-201
   PubMed Web of Science ®Google Scholar
• van der Klaauw AA, Bax JJ, Roelfsema F, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 2006;16(2):101-7
   PubMed Web of Science ®Google Scholar
• van der Klaauw AA, Bax JJ, Smit JW, et al. Increased aortic root diameters in patients with acromegaly. Eur J Endocrinol 2008;159(2):97-103
   PubMed Web of Science ®Google Scholar
• Moller N, Schmitz O, Moller J, Butler PC. Effects of a physiological growth hormone pulse on substrate metabolism in insulin-dependent (type 1) diabetic subjects. J Clin Endocrinol Metab 1992;75(2):432-6
   PubMed Web of Science ®Google Scholar
• O’Sullivan AJ, Kelly JJ, Hoffman DM, et al. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 1994;78(2):381-6
   PubMed Web of Science ®Google Scholar
• Stelmachowska-Banas M, Zielinski G, Zdunowski P, et al. The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol Neurochir Pol 2011;45(4):328-34
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94(5):1500-8
   PubMed Web of Science ®Google Scholar
• Arosio M, Macchelli S, Rossi CM, et al. Effects of treatment with octreotide in acromegalic patients–a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995;133(4):430-9
   PubMed Web of Science ®Google Scholar
• Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract 2011;17(Suppl 4):1-44
   PubMedGoogle Scholar
• Ronchi CL, Orsi E, Giavoli C, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 2003;26(6):533-8
   PubMed Web of Science ®Google Scholar
• Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005;90(10):5684-91
   PubMed Web of Science ®Google Scholar
• Lindberg-Larsen R, Moller N, Schmitz O, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 2007;92(5):1724-8
   PubMed Web of Science ®Google Scholar
• Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007;92(1):190-5
   PubMed Web of Science ®Google Scholar
• Gibney J, Wolthers T, Burt MG, et al. Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 2007;92(4):1479-84
   PubMed Web of Science ®Google Scholar
• Katznelson L. Alterations in body composition in acromegaly. Pituitary 2009;12(2):136-42
   PubMed Web of Science ®Google Scholar
• Goodman HM, Grichting G. Growth hormone and lipolysis: a reevaluation. Endocrinology 1983;113(5):1697-702
   PubMed Web of Science ®Google Scholar
• Bolanowski M, Milewicz A, Bidzinska B, et al. Serum leptin levels in acromegaly–a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 2002;8(10):CR685-9
   PubMedGoogle Scholar
• Tominaga A, Arita K, Kurisu K, et al. Effects of successful adenomectomy on body composition in acromegaly. Endocr J 1998;45(3):335-42
   PubMed Web of Science ®Google Scholar
• Sucunza N, Barahona MJ, Resmini E, et al. Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol 2008;159(6):773-9
   PubMed Web of Science ®Google Scholar
• Huang X, Blackman MR, Herreman K, et al. Effects of growth hormone and/or sex steroid administration on whole-body protein turnover in healthy aged women and men. Metabolism 2005;54(9):1162-7
   PubMed Web of Science ®Google Scholar
• Brummer RJ, Lonn L, Kvist H, et al. Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. Eur J Clin Invest 1993;23(4):199-205
   PubMed Web of Science ®Google Scholar
• Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89(2):658-61
   PubMed Web of Science ®Google Scholar
• Roemmler J, Otto B, Steffin B, et al. Serum leptin and ghrelin levels in active and inactive acromegalic patients during an oral glucose tolerance test. Exp Clin Endocrinol Diabetes 2009;117(3):135-41
   PubMed Web of Science ®Google Scholar
• Oscarsson J, Wiklund O, Jakobsson KE, et al. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clin Endocrinol (Oxf) 1994;41(5):603-8
   PubMed Web of Science ®Google Scholar
• Boero L, Manavela M, Merono T, et al.H levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin Endocrinol (Oxf) 2012;77(4):579-85
   PubMed Web of Science ®Google Scholar
• Maldonado Castro GF, Escobar-Morreale HF, Ortega H, et al. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clin Endocrinol (Oxf) 2000;53(3):313-19
   PubMed Web of Science ®Google Scholar
• Vilar L, Naves LA, Costa SS, et al. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 2007;13(4):363-72
   PubMedGoogle Scholar
• Wildbrett J, Hanefeld M, Fucker K, et al. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 1997;105(6):331-5
   PubMed Web of Science ®Google Scholar
• Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005;20(10):1837-44
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357(9):905-16
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 2008;93(12):4649-55
   PubMed Web of Science ®Google Scholar
• Battista C, Chiodini I, Muscarella S, et al. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol (Oxf) 2009;70(3):378-82
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Hamdy NA, Pereira AM, et al. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. Eur J Endocrinol 2005;152(1):53-60
   PubMed Web of Science ®Google Scholar
• Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 2006;24(1):72-8
   PubMed Web of Science ®Google Scholar
• Lesse GP, Fraser WD, Farquharson R, et al. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf) 1998;48(1):59-65
   PubMed Web of Science ®Google Scholar
• Scillitani A, Battista C, Chiodini I, et al. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin Endocrinol (Oxf) 2003;58(6):725-31
   PubMed Web of Science ®Google Scholar
• Seeman E, Wahner HW, Offord KP, et al. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 1982;69(6):1302-9
   PubMed Web of Science ®Google Scholar
• Ueland T, Ebbesen EN, Thomsen JS, et al. Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest 2002;32(2):122-8
   PubMed Web of Science ®Google Scholar
• Brzana J, Yedinak CG, Hameed N, Fleseriu M. FRAX score in acromegaly: does it tell the whole story? Clin Endocrinol (Oxf) 2014;80(4):614-16
   PubMedGoogle Scholar
• Madeira M, Neto LV, Torres CH, et al. Vertebral fracture assessment in acromegaly. J Clin Densitom 2013;16(2):238-43
   PubMed Web of Science ®Google Scholar
• Padova G, Borzi G, Incorvaia L, et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab 2011;8(3):37-43
   PubMedGoogle Scholar
• Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 2011;164(4):475-83
   PubMed Web of Science ®Google Scholar
• Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 2013;98(12):4808-15
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 2013;98(8):3402-10
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29(5):535-59
   PubMed Web of Science ®Google Scholar
• Roelfsema F, van der Sluys J, Smeenk D. Quantitation of bone and bone turnover in biopsy specimens from the iliac crest in acromegaly. J Endocrinol 1970;48(4):lxi
   PubMed Web of Science ®Google Scholar
• Romijn JA. Acromegalic arthropathy: current perspectives. Endocrine 2013;43(2):245-6
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013;16(3):294-302
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Bianchi A, et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 2010;163(1):15-20
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol 2014;170(6):893-9
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005;90(5):2731-9
   PubMed Web of Science ®Google Scholar
• Barkan AL. Acromegalic arthropathy. Pituitary 2001;4(4):263-4
   PubMedGoogle Scholar
• Wassenaar MJ, Biermasz NR, van DN, et al. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. Eur J Endocrinol 2009;160(3):357-65
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Vallone G, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998;83(6):2121-5
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) 1999;51(5):611-18
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van’t KR, Wassenaar MJ, et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol 2012;166(3):407-13
   PubMed Web of Science ®Google Scholar
• Wassenaar MJ, Biermasz NR, Bijsterbosch J, et al. Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 2011;70(2):320-5
   PubMed Web of Science ®Google Scholar
• Claessen KM, Ramautar SR, Pereira AM, et al. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol 2012;167(2):235-44
   PubMed Web of Science ®Google Scholar
• Claessen KM, Ramautar SR, Pereira AM, et al. Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary 2014;17(1):44-52
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Pereira AM, Frolich M, et al. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. Am J Physiol Endocrinol Metab 2004;286(1):E25-30
   PubMed Web of Science ®Google Scholar
• Layton MW, Fudman EJ, Barkan A, et al. Acromegalic arthropathy. Characteristics and response to therapy. Arthritis Rheum 1988;31(8):1022-7
   PubMed Web of Science ®Google Scholar
• Dons RF, Rosselet P, Pastakia B, et al. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf) 1988;28(5):515-24
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Wassenaar MJ, van der Klaauw AA, et al. Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. J Clin Endocrinol Metab 2009;94(7):2374-9
   PubMed Web of Science ®Google Scholar
• Wassenaar MJ, Biermasz NR, Pereira AM, et al. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab 2009;94(12):4671-8
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89(6):2789-96
   PubMed Web of Science ®Google Scholar
• Scarpa R, De BD, Pivonello R, et al. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab 2004;89(2):598-603
   PubMed Web of Science ®Google Scholar
• Colao A, Balzano A, Ferone D, et al. Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol (Oxf) 1997;47(1):23-8
   PubMed Web of Science ®Google Scholar
• Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995;80(11):3223-6
   PubMed Web of Science ®Google Scholar
• Ezzat S, Melmed S. Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991;72(2):245-9
   PubMed Web of Science ®Google Scholar
• Pines A, Rozen P, Ron E, Gilat T. Gastrointestinal tumors in acromegalic patients. Am J Gastroenterol 1985;80(4):266-9
   PubMed Web of Science ®Google Scholar
• Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 2008;14(22):3484-9
   PubMed Web of Science ®Google Scholar
• Lahm H, Suardet L, Laurent PL, et al. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br J Cancer 1992;65(3):341-6
   PubMed Web of Science ®Google Scholar
• Simmons JG, Pucilowska JB, Lund PK. Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors. Am J Physiol 1999;276(4 Pt 1):G817-G827
   PubMed Web of Science ®Google Scholar
• Ferbeyre G, Moriggl R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta 2011;1815(1):104-14
   PubMed Web of Science ®Google Scholar
• Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008;15(2):367-90
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. J Clin Endocrinol Metab 2007;92(10):3854-60
   PubMed Web of Science ®Google Scholar
• Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer 1991;68(8):1673-7
   PubMed Web of Science ®Google Scholar
• Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83(8):2730-4
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 2001;86(7):2929-34
   PubMed Web of Science ®Google Scholar
• Wassenaar MJ, Cazemier M, Biermasz NR, et al. Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab 2010;95(5):2073-9
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Fairclough PD. Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 2002;51(Suppl 5):V13-14
   PubMed Web of Science ®Google Scholar
• Lois K, Bukowczan J, Perros P, et al. The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary 2014;18(4):568-74
   Web of Science ®Google Scholar
• Dworakowska D, Gueorguiev M, Kelly P, et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol 2010;163(1):21-8
   PubMed Web of Science ®Google Scholar
• Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991;115(7):527-32
   PubMed Web of Science ®Google Scholar
• Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994;121(7):478-83
   PubMed Web of Science ®Google Scholar
• Grunstein RR, Ho KY, Berthon-Jones M, et al. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am J Respir Crit Care Med 1994;150(2):496-502
   PubMed Web of Science ®Google Scholar
• Hochban W, Ehlenz K, Conradt R, Brandenburg U. Obstructive sleep apnoea in acromegaly: the role of craniofacial changes. Eur Respir J 1999;14(1):196-202
   PubMed Web of Science ®Google Scholar
• Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004;151(3):309-15
   PubMed Web of Science ®Google Scholar
• Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 2001;55(4):477-83
   PubMed Web of Science ®Google Scholar
• Barkan A. Acromegalic arthropathy and sleep apnea. J Endocrinol 1997;155(Suppl 1):S41-S44
   PubMedGoogle Scholar
• Piper JG, Dirks BA, Traynelis VC, VanGilder JC. Perioperative management and surgical outcome of the acromegalic patient with sleep apnea. Neurosurgery 1995;36(1):70-4
   PubMed Web of Science ®Google Scholar
• Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 2007;156(3):321-9
   PubMed Web of Science ®Google Scholar
• Davi’ MV, Dalle CL, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 2008;159(5):533-40
   PubMed Web of Science ®Google Scholar
• Pekkarinen T, Partinen M, Pelkonen R, Iivanainen M. Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors. Clin Endocrinol (Oxf) 1987;27(6):649-54
   PubMed Web of Science ®Google Scholar
• Pelttari L, Polo O, Rauhala E, et al. Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin Endocrinol (Oxf) 1995;43(2):175-82
   PubMed Web of Science ®Google Scholar
• Pereira AM, Tiemensma J, Romijn JA, Biermasz NR. Cognitive impairment and psychopathology in patients with pituitary diseases. Neth J Med 2012;70(6):255-60
   PubMed Web of Science ®Google Scholar
• Santos A, Resmini E, Martinez MA, et al. Quality of life in patients with pituitary tumors. Curr Opin Endocrinol Diabetes Obes 2009;16(4):299-303
   PubMed Web of Science ®Google Scholar
• Tiemensma J, Biermasz NR, van der Mast RC, et al. Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J Clin Endocrinol Metab 2010;95(12):E392-402
   PubMed Web of Science ®Google Scholar
• Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006;83(3-4):224-9
   PubMed Web of Science ®Google Scholar
• Tiemensma J, Kaptein AA, Pereira AM, et al. Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab 2011;96(11):3550-8
   PubMed Web of Science ®Google Scholar
• Andela CD, Scharloo M, Pereira AM, et al. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 2015. [Epub ahead of print]
   Google Scholar
• Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12(1):71-9
   PubMed Web of Science ®Google Scholar
• Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58(1):86-91
   PubMed Web of Science ®Google Scholar
• Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89(4):1613-17
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89(2):667-74
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159(2):89-95
   PubMed Web of Science ®Google Scholar
• Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005;90(7):4081-6
   PubMed Web of Science ®Google Scholar
• Colao A, Vandeva S, Pivonello R, et al. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). Eur J Endocrinol 2014;171(2):263-73
   PubMed Web of Science ®Google Scholar
• Mercado M, Gonzalez B, Vargas G, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 2014;99(12):4438-46
   PubMed Web of Science ®Google Scholar
• Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336(8710):285-8
   PubMed Web of Science ®Google Scholar
• Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev 2010;31(3):301-42
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357(9254):425-31
   PubMed Web of Science ®Google Scholar
• Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009;94(11):4216-23
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW. Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13(4):185-92
   PubMed Web of Science ®Google Scholar
• Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41(1):95-102
   PubMed Web of Science ®Google Scholar